

<b>eCQM Title</b>	<b>Intravesical Bacillus-Calmette-Guerin for Non-Muscle Invasive Bladder Cancer</b>		
<b>eCQM Identifier (Measure Authoring Tool)</b>	646	<b>eCQM Version Number</b>	5.2.000
<b>CBE Number</b>	Not Applicable	<b>GUID</b>	224b1722-aef9-4e7f-97f8-284267fc1b00
<b>Measurement Period</b>	January 1, 20XX through December 31, 20XX		
<b>Measure Steward</b>	Oregon Urology		
<b>Measure Developer</b>	Oregon Urology		
<b>Endorsed By</b>	None		
<b>Description</b>	<p>Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging</p> <p>Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. Oregon Urology Institute (OUI) and Large Urology Group Practice Association (LUGPA) disclaim all liability for use or accuracy of third party codes contained in the specifications.</p>		
<b>Copyright</b>	<p>CPT(R) contained in the Measure specifications is copyright 2004-2023. American Medical Association. LOINC(R) copyright 2004-2023 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2023 International Health Terminology Standards Development Organisation. ICD-10 copyright 2023 World Health Organization. All Rights Reserved.</p> <p>The performance measure is not a clinical guideline and does not establish a standard of medical care, and has not been tested for all potential applications.</p>		
<b>Disclaimer</b>	<p>THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.</p> <p>Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by TM or [TM].</p>		
<b>Measure Scoring</b>	Proportion		
<b>Measure Type</b>	Process		
<b>Stratification</b>	None		
<b>Risk Adjustment</b>	None		
<b>Rate Aggregation</b>	None		
<b>Rationale</b>	<p>Bladder cancer is ranked 10th for new cancer cases in 2020 and is the 9th leading cause of cancer death in the United States. There are 81,400 estimated new cases in 2020 and 17,980 estimated deaths in 2020. In 2016, there were an estimated 699,450 people living with bladder cancer in the United States. Early detection (discovery of cancer in situ or localized to the primary site) is found in 85% of the patients, and with these there is a five-year survival rate of 95.8% for In Situ and 69.2% for Localized. Bladder cancer is rarely found in patients under age 20, with the median age of diagnosis being 73 (NIH, 2020).</p> <p>National Comprehensive Cancer Network (NCCN) Guidelines for Bladder Cancer (version 6.2021) defines intravesical BCG as Category 1 Treatment for Ta - high grade, T1 and Tis non-muscle invasive bladder cancer. Most public data reflects prophylactic or adjuvant use of intravesical therapy with the goal of preventing recurrence or delaying progression to a higher grade or stage. BCG has been shown to be effective as prophylaxis to prevent bladder cancer recurrences following TURBT. The NCCN Bladder Cancer Panel Members recommend BCG as the preferred option over Mitomycin C for adjuvant treatment of high-grade lesions (Ta). BCG is also standard therapy for Primary Tis. Most T1 lesions are high risk and are similarly treated with adjuvant intravesical therapy with BCG being a Category 1 recommendation. (NCCN, 2021).</p>		
<b>Clinical Recommendation</b>	<p>Intravesical BCG should be administered within 6 months of the initial diagnosis of non-muscle invasive bladder cancer. It may be administered 3-4 weeks after resection, but there needs to be pathological tumor confirmation and</p>		

<b>Statement</b>	must be withheld if there is traumatic catheterization, bacteriuria, persistent gross hematuria, persistent severe local symptoms or systemic symptoms. The normal induction course is 6 weekly instillations of intravesical BCG (AUA Non-Muscle Invasive Bladder Cancer and American Urological Association (AUA) Guideline for the Management of Non-muscle Invasive Bladder Cancer: Stages Ta High Risk, T1 and TIS).
<b>Improvement Notation</b>	A higher score is the preferred result and indicates better quality Reference Type: CITATION
<b>Reference</b>	Reference Text: 'Chamie, K., Saigal, C.S., Lai, J., Hanley, J.M., Setodji, C.M., Konety, B.R., Litwin, M.S., & Urologic Diseases in America Project (2011). Compliance with Guidelines for Patients with Bladder Cancer: Variation in the Delivery of Care. Cancer.2011 Dec 1: 117(23): 5392--5401. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206145/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206145/</a> Reference Type: CITATION
<b>Reference</b>	Reference Text: 'Chang, S.S., Boorjian, S.A., Chou, R., Clark, P.E., Daneshmand, S., Konety, B.R., Pruthi, R., Quale, D.Z., Ritch, C.R., Seigne, J.D., Skinner, E.C., Smith, N.M., & Mckiernan, J. M., (2016) American Urological Association. Non-Muscle Invasive Bladder Cancer. <a href="https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline">https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline</a> Reference Type: CITATION
<b>Reference</b>	Reference Text: 'Hall, M.C., Chang, S.S., Dalbagni, G., Pruthi, R.S., Schellhammer, P.F., Seigne, J.D., Skinner, E.C., & Wolf .S., (2016). American Urological Association. Guideline for the Management of Non-muscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): Update 2016. <a href="https://www.auajournals.org/doi/10.1016/j.juro.2007.09.003">https://www.auajournals.org/doi/10.1016/j.juro.2007.09.003</a> Reference Type: CITATION
<b>Reference</b>	Reference Text: 'Kassouf, W., Black, P., (2016) Treatment of primary non-muscle invasive urothelial bladder cancer. Literature review current through Dec. 2016. <a href="https://www.uptodate.com/contents/treatment-of-primary-non-muscle-invasive-urothelial-bladder-cancer?source=search_result&amp;search=Treatment%20of%20primary%20non-muscle%20invasive%20urothelial%20bladder%20cancer&amp;selectedTitle=1~150 T of primary">https://www.uptodate.com/contents/treatment-of-primary-non-muscle-invasive-urothelial-bladder-cancer?source=search_result&amp;search=Treatment%20of%20primary%20non-muscle%20invasive%20urothelial%20bladder%20cancer&amp;selectedTitle=1~150 T of primary</a> Reference Type: CITATION
<b>Reference</b>	Reference Text: 'NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). (2021). Bladder Cancer. Version 6.2021. <a href="https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf">https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf</a> Reference Type: CITATION
<b>Reference</b>	Reference Text: 'NIH National Cancer Institute Surveillance, (2020) Epidemiology, and End Results Program. SEER Cancer Stat Facts: Bladder Cancer. National Cancer Institute. Bethesda,MD, <a href="https://seer.cancer.gov/statfacts/html/urinb.html">https://seer.cancer.gov/statfacts/html/urinb.html</a> Reference Type: CITATION
<b>Reference</b>	Reference Text: 'Pacific Northwest Evidence-based Practice Center, Oregon Health & Science University. (2016). PCORI Topic Brief. Comparative Effectiveness of Treatments for Non-Muscle-Invasive Bladder Cancer <a href="http://www.pcori.org/sites/default/files/PCORI-Assessment-Options-Advisory-Panel-Fall-2016-Topic-Brief-Non-Muscle-Invasive-Bladder-Cancer.pdf">http://www.pcori.org/sites/default/files/PCORI-Assessment-Options-Advisory-Panel-Fall-2016-Topic-Brief-Non-Muscle-Invasive-Bladder-Cancer.pdf</a>
<b>Definition</b>	Intravesical - Within the urinary bladder Bacillus Calmette-Guerin (BCG) - A live attenuated strain of Mycobacterium bovis, first indicated as a tuberculosis vaccine, has had widespread use in intravesical immunotherapy since the 1970's. Tumor location: urinary bladder Histology: urothelial carcinoma Primary Tumor (T) stage: Ta - Noninvasive and high grade Tis - Carcinoma in situ: "flat tumor" T1- tumor invades subepithelial connective tissue (high grade or low grade)

<b>Guidance</b>	<p>Ta bladder cancer must be high grade Ta only and is supported by the 2016 AUA guidelines and 2018 NCCN guidelines.</p> <p>The BCG dose can be full or partial and can be from any lot or manufacturer.</p> <p>This eCQM is a patient-based measure.</p> <p>Telehealth encounters are not eligible for this measure because the measure requires a clinical action that cannot be conducted via telehealth.</p> <p>This version of the eCQM uses QDM version 5.6. Please refer to the eCQI resource center (<a href="https://ecqi.healthit.gov/qdm">https://ecqi.healthit.gov/qdm</a>) for more information on the QDM.</p>
<b>Transmission Format</b>	TBD
<b>Initial Population</b>	All patients initially diagnosed with T1, Tis or high grade Ta non-muscle invasive bladder cancer with bladder cancer staging within 6 months before to 6 months after the start of the measurement period and a qualified encounter in the measurement period
<b>Denominator</b>	<p>Equals Initial Population</p> <p>Immunosuppressed patients, includes HIV and immunocompromised state, with a diagnosis prior to Bladder Cancer Staging.</p> <p>Immunosuppressive drug therapy starting on or before Bladder Cancer Staging.</p>
<b>Denominator Exclusions</b>	<p>Active Tuberculosis diagnosis during the Bladder Cancer Staging.</p> <p>Mixed histology urothelial cell carcinoma including micropapillary, plasmacytoid, sarcomatoid, adenocarcinoma and squamous disease prior to Bladder Cancer Staging.</p> <p>Patients who undergo cystectomy, chemotherapy or radiation within 6 months prior to Bladder Cancer Staging.</p>
<b>Numerator</b>	Intravesical Bacillus-Calmette Guerin (BCG) instillation for initial dose or series: BCG is initiated within 6 months of the bladder cancer staging
<b>Numerator Exclusions</b>	Not Applicable
<b>Denominator Exceptions</b>	Unavailability of BCG within 6 months after Bladder Cancer Staging
<b>Supplemental Data Elements</b>	For every patient evaluated by this measure also identify payer, race, ethnicity and sex

## Table of Contents

- [Population Criteria](#)
- [Definitions](#)
- [Functions](#)
- [Terminology](#)
- [Data Criteria \(QDM Data Elements\)](#)
- [Supplemental Data Elements](#)
- [Risk Adjustment Variables](#)

## [Population Criteria](#)

### ▲ Initial Population

"Has Most Recent Bladder Cancer Tumor Staging is Ta HG, Tis, T1"  
and "Has Qualifying Encounter"

**▲ Denominator**

"Initial Population"

**▲ Denominator Exclusions**

exists "Acute Tuberculosis Diagnosis"  
 or exists "Immunosuppressive Drugs"  
 or exists "Cystectomy Done"  
 or "Has Excluding HIV, Immunocompromised Conditions or Mixed Histology Before Staging"  
 or "Has Excluding Chemotherapy or Radiotherapy Procedure Before Staging"

**▲ Numerator**

"First BCG Administered" is not null

**▲ Numerator Exclusions**

None

**▲ Denominator Exceptions**

exists "BCG Not Available Within 6 Months After Bladder Cancer Staging"

**▲ Stratification**

None

**Definitions****▲ Acute Tuberculosis Diagnosis**

[ "Diagnosis": "Active Tuberculosis for Urology Care" ] ActiveTuberculosis  
 with "First Bladder Cancer Staging Procedure" FirstBladderCancerStaging  
 such that ActiveTuberculosis.prevalencePeriod overlaps after day of Global."NormalizeInterval" ( FirstBladderCancerStaging.relevantDatetime,  
 FirstBladderCancerStaging.relevantPeriod )

**▲ BCG Not Available Within 6 Months After Bladder Cancer Staging**

( [ "Medication, Not Administered": "BCG Bacillus Calmette Guerin for Urology Care" ] BCGnotGiven  
 with "First Bladder Cancer Staging Procedure" FirstBladderCancerStaging  
 such that BCGnotGiven.authorDatetime 6 months or less after start of Global."NormalizeInterval" ( FirstBladderCancerStaging.relevantDatetime,  
 FirstBladderCancerStaging.relevantPeriod )  
 where BCGnotGiven.negationRationale in "Unavailability of Bacillus Calmette Guerin for urology care"  
 )

**▲ Bladder Cancer Diagnosis**

[ "Diagnosis": "Bladder Cancer for Urology Care" ] BladderCancer  
 where BladderCancer.prevalencePeriod starts before end of "Measurement Period"

**▲ Cystectomy Done**

[ "Procedure, Performed": "Cystectomy for Urology Care" ] Cystectomy  
 with "First Bladder Cancer Staging Procedure" FirstBladderCancerStaging  
 such that Global.EarliestOf ( Cystectomy.relevantDatetime, Cystectomy.relevantPeriod ) 6 months or less before start of Global."NormalizeInterval" ( FirstBladderCancerStaging.relevantDatetime, FirstBladderCancerStaging.relevantPeriod )

#### ▲ Denominator

"Initial Population"

#### ▲ Denominator Exception

exists "BCG Not Available Within 6 Months After Bladder Cancer Staging"

#### ▲ Denominator Exclusion

exists "Acute Tuberculosis Diagnosis"  
 or exists "Immunosuppressive Drugs"  
 or exists "Cystectomy Done"  
 or "Has Excluding HIV, Immunocompromised Conditions or Mixed Histology Before Staging"  
 or "Has Excluding Chemotherapy or Radiotherapy Procedure Before Staging"

#### ▲ First BCG Administered

First([ "Medication, Administered": "BCG Bacillus Calmette Guerin for Urology Care" ] BCG  
 with "First Bladder Cancer Staging Procedure" FirstBladderCancerStaging  
 such that Global."NormalizeInterval"(BCG.relevantDatetime, BCG.relevantPeriod) starts 6 months or less after start of Global."NormalizeInterval"  
 (FirstBladderCancerStaging.relevantDatetime, FirstBladderCancerStaging.relevantPeriod)  
 sort by start of Global."NormalizeInterval"(relevantDatetime, relevantPeriod)  
 )

#### ▲ First Bladder Cancer Staging Procedure

First([ "Procedure, Performed": "Tumor staging (tumor staging)" ] BladderCancerStaging  
 with "Bladder Cancer Diagnosis" BladderCancer  
 such that Global."NormalizeInterval"(BladderCancerStaging.relevantDatetime, BladderCancerStaging.relevantPeriod) starts on or before day of start  
 BladderCancer.prevalencePeriod  
 sort by start of Global."NormalizeInterval"(relevantDatetime, relevantPeriod)  
 )

#### ▲ First Bladder Cancer Staging Procedure during 6 Months Prior to Measurement Period through the First 6 Months of Measurement Period

"First Bladder Cancer Staging Procedure" FirstBladderCancerStaging  
 where Global."NormalizeInterval" ( FirstBladderCancerStaging.relevantDatetime, FirstBladderCancerStaging.relevantPeriod ) during day of Interval["July 1 of Year Prior  
 to the Measurement Period", "June 30 of the Measurement Period"]

#### ▲ Has Excluding HIV, Immunocompromised Conditions or Mixed Histology Before Staging

exists ( ( [ "Diagnosis": "HIV"  
 union [ "Diagnosis": "Immunocompromised Conditions"  
 union [ "Diagnosis": "Mixed histology urothelial cell carcinoma for Urology Care" ] ) ExclusionDiagnosis  
 with "First Bladder Cancer Staging Procedure" FirstBladderCancerStaging  
 such that ExclusionDiagnosis.prevalencePeriod starts on or before day of start of Global."NormalizeInterval" ( FirstBladderCancerStaging.relevantDatetime,  
 FirstBladderCancerStaging.relevantPeriod )  
 )

#### ▲ Has Excluding Chemotherapy or Radiotherapy Procedure Before Staging

exists ( ( [ "Medication, Active": "Chemotherapy Agents for Advanced Cancer"  
 union [ "Procedure, Performed": "Combined radiotherapy (procedure)" ] ) ExclusionMedsProcedures

with "First Bladder Cancer Staging Procedure" FirstBladderCancerStaging  
 such that ExclusionMedsProcedures.relevantPeriod starts 6 months or less before Global."NormalizeInterval" ( FirstBladderCancerStaging.relevantDatetime,  
 FirstBladderCancerStaging.relevantPeriod )  
 )

#### ▲ Has Most Recent Bladder Cancer Tumor Staging is Ta HG, Tis, T1

( "First Bladder Cancer Staging Procedure during 6 Months Prior to Measurement Period through the First 6 Months of Measurement Period" FirstBladderCancerStagingMP  
 where FirstBladderCancerStagingMP.result ~ "American Joint Committee on Cancer cT1 (qualifier value)"  
 or FirstBladderCancerStagingMP.result ~ "American Joint Committee on Cancer cTis (qualifier value)"  
 or FirstBladderCancerStagingMP.result ~ "American Joint Committee on Cancer cTa (qualifier value)"  
 or FirstBladderCancerStagingMP.result ~ "Carcinoma in situ of bladder"  
 ) is not null

#### ▲ Has Qualifying Encounter

exists ["Encounter, Performed": "Office Visit"] ValidEncounter  
 where ValidEncounter.relevantPeriod during day of "Measurement Period"  
 and ValidEncounter.class !~ "virtual"

#### ▲ Immunosuppressive Drugs

["Medication, Active": "Immunosuppressive Drugs for Urology Care"] ImmunosuppressiveDrugs  
 with "First Bladder Cancer Staging Procedure" FirstBladderCancerStaging  
 such that Global."NormalizeInterval" ( ImmunosuppressiveDrugs.relevantDatetime, ImmunosuppressiveDrugs.relevantPeriod ) starts on or before day of start of  
 Global."NormalizeInterval" ( FirstBladderCancerStaging.relevantDatetime, FirstBladderCancerStaging.relevantPeriod )

#### ▲ Initial Population

"Has Most Recent Bladder Cancer Tumor Staging is Ta HG, Tis, T1"  
 and "Has Qualifying Encounter"

#### ▲ July 1 of Year Prior to the Measurement Period

DateTime((year from start of "Measurement Period" - 1), 7, 1, 0, 0, 0, 0)

#### ▲ June 30 of the Measurement Period

DateTime((year from start of "Measurement Period"), 6, 30, 23, 59, 59, 0, 0)

#### ▲ Numerator

"First BCG Administered" is not null

#### ▲ SDE Ethnicity

["Patient Characteristic Ethnicity": "Ethnicity"]

#### ▲ SDE Payer

["Patient Characteristic Payer": "Payer Type"]

#### ▲ SDE Race

["Patient Characteristic Race": "Race"]

#### ▲ SDE Sex

["Patient Characteristic Sex": "ONC Administrative Sex"]

## Functions

### ▲ Global.Earliest(period Interval<DateTime>)

```
if ( HasStart(period)) then start of period
else
end of period
```

### ▲ Global.EarliestOf(pointInTime DateTime, period Interval<DateTime>)

```
Earliest(NormalizeInterval(pointInTime, period))
```

### ▲ Global.HasStart(period Interval<DateTime>)

```
not ( start of period is null
or start of period = minimum DateTime
)
```

### ▲ Global.NormalizeInterval(pointInTime DateTime, period Interval<DateTime>)

```
if pointInTime is not null then Interval[pointInTime, pointInTime]
else if period is not null then period
else null as Interval<DateTime>
```

## Terminology

- code "American Joint Committee on Cancer cT1 (qualifier value)" ("SNOMEDCT Code (1228889001)")
- code "American Joint Committee on Cancer cTa (qualifier value)" ("SNOMEDCT Code (1228883000)")
- code "American Joint Committee on Cancer cTis (qualifier value)" ("SNOMEDCT Code (1228884006)")
- code "Carcinoma in situ of bladder" ("ICD10CM Code (D09.0)")
- code "Combined radiotherapy (procedure)" ("SNOMEDCT Code (169331000)")
- code "Tumor staging (tumor staging)" ("SNOMEDCT Code (254292007)")
- code "virtual" ("ActCode Code (VR)")
- valueset "Active Tuberculosis for Urology Care" (2.16.840.1.113762.1.4.1151.56)
- valueset "BCG Bacillus Calmette Guerin for Urology Care" (2.16.840.1.113762.1.4.1151.52)
- valueset "Bladder Cancer for Urology Care" (2.16.840.1.113762.1.4.1151.45)
- valueset "Chemotherapy Agents for Advanced Cancer" (2.16.840.1.113762.1.4.1151.60)
- valueset "Cystectomy for Urology Care" (2.16.840.1.113762.1.4.1151.55)
- valueset "Ethnicity" (2.16.840.1.114222.4.11.837)
- valueset "HIV" (2.16.840.1.113883.3.464.1003.120.12.1003)
- valueset "Immunocompromised Conditions" (2.16.840.1.113883.3.666.5.1940)
- valueset "Immunosuppressive Drugs for Urology Care" (2.16.840.1.113762.1.4.1151.32)
- valueset "Mixed histology urothelial cell carcinoma for Urology Care" (2.16.840.1.113762.1.4.1151.39)
- valueset "Office Visit" (2.16.840.1.113883.3.464.1003.101.12.1001)
- valueset "ONC Administrative Sex" (2.16.840.1.113762.1.4.1)
- valueset "Payer Type" (2.16.840.1.114222.4.11.3591)
- valueset "Race" (2.16.840.1.114222.4.11.836)
- valueset "Unavailability of Bacillus Calmette Guerin for urology care" (2.16.840.1.113762.1.4.1151.44)

## Data Criteria (QDM Data Elements)

- "Diagnosis: Active Tuberculosis for Urology Care" using "Active Tuberculosis for Urology Care (2.16.840.1.113762.1.4.1151.56)"
- "Diagnosis: Bladder Cancer for Urology Care" using "Bladder Cancer for Urology Care (2.16.840.1.113762.1.4.1151.45)"
- "Diagnosis: HIV" using "HIV (2.16.840.1.113883.3.464.1003.120.12.1003)"
- "Diagnosis: Immunocompromised Conditions" using "Immunocompromised Conditions (2.16.840.1.113883.3.666.5.1940)"

- "Diagnosis: Mixed histology urothelial cell carcinoma for Urology Care" using "Mixed histology urothelial cell carcinoma for Urology Care (2.16.840.1.113762.1.4.1151.39)"
- "Encounter, Performed: Office Visit" using "Office Visit (2.16.840.1.113883.3.464.1003.101.12.1001)"
- "Medication, Active: Chemotherapy Agents for Advanced Cancer" using "Chemotherapy Agents for Advanced Cancer (2.16.840.1.113762.1.4.1151.60)"
- "Medication, Active: Immunosuppressive Drugs for Urology Care" using "Immunosuppressive Drugs for Urology Care (2.16.840.1.113762.1.4.1151.32)"
- "Medication, Administered: BCG Bacillus Calmette Guerin for Urology Care" using "BCG Bacillus Calmette Guerin for Urology Care (2.16.840.1.113762.1.4.1151.52)"
- "Medication, Not Administered: BCG Bacillus Calmette Guerin for Urology Care" using "BCG Bacillus Calmette Guerin for Urology Care (2.16.840.1.113762.1.4.1151.52)"
- "Patient Characteristic Ethnicity: Ethnicity" using "Ethnicity (2.16.840.1.114222.4.11.837)"
- "Patient Characteristic Payer: Payer Type" using "Payer Type (2.16.840.1.114222.4.11.3591)"
- "Patient Characteristic Race: Race" using "Race (2.16.840.1.114222.4.11.836)"
- "Patient Characteristic Sex: ONC Administrative Sex" using "ONC Administrative Sex (2.16.840.1.113762.1.4.1)"
- "Procedure, Performed: Combined radiotherapy (procedure)" using "Combined radiotherapy (procedure) (SNOMEDCT Code 169331000)"
- "Procedure, Performed: Cystectomy for Urology Care" using "Cystectomy for Urology Care (2.16.840.1.113762.1.4.1151.55)"
- "Procedure, Performed: Tumor staging (tumor staging)" using "Tumor staging (tumor staging) (SNOMEDCT Code 254292007)"

### **Supplemental Data Elements**

#### **▲ SDE Ethnicity**

["Patient Characteristic Ethnicity": "Ethnicity"]

#### **▲ SDE Payer**

["Patient Characteristic Payer": "Payer Type"]

#### **▲ SDE Race**

["Patient Characteristic Race": "Race"]

#### **▲ SDE Sex**

["Patient Characteristic Sex": "ONC Administrative Sex"]

### **Risk Adjustment Variables**

None

Measure Set	None
-------------	------